HDAC6-IN-63

HDAC6-IN-63 (Compound 7) is an orally active HDAC6 inhibitor with an IC50 of 145 nM. HDAC6-IN-63 inhibits the expression of Sp1 and RAD51, thereby inducing Caspase-dependent apoptosis. HDAC6-IN-63 has antitumor activity and sensitizes Etoposide (HY-13629) and Gemcitabine (HY-17026), promoting synergistic death of NSCLC cells through the inhibition of homologous recombination and non-homologous end joining (NHEJ) pathways involved in DNA DSB repair. HDAC6-IN-63 can be used for chemotherapy of cancers like NSCLC research[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; Caspase; DNA/RNA Synthesis; HDAC; RAD51

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Field of Research

Cancer

Smiles

O=C(N(C(C1=CC=CC=C12)=O)CCC3=CC=CC=C3)N2CC(C=C4)=CC=C4NC(CS)=O

Molecular Formula

C25H23N3O3S

Molecular Weight

445.53

References & Citations

[1]Huang HC, et al. Establishing a noncanonical zinc-binding group as a selective histone deacetylase inhibitor and possible novel anticancer agent. Bioorg Chem. 2025 Aug 27;165:108917.